Intrinsic4D Inc.
TSX VENTURE : IFD

June 15, 2016 16:00 ET

Intrinsic4D Announces Insurance Carrier Update, Board Changes and Option Grant

BLOOMFIELD HILLS, MICHIGAN--(Marketwired - June 15, 2016) - Intrinsic4D Inc. ("Intrinsic4D") (TSX VENTURE:IFD) announced today that its Authentic4D Medical-Legal platform continues to receive market validation and has doubled the number of insurance enterprise clients over the last quarter. Intrinsic4D is now working with more than 15 insurance carriers, the majority of which are amongst the top 25 U.S. automobile insurance providers.

Additionally, Intrinsic4D announces the departure from the board of directors of Mr. Mark Klopp who will be moving on to focus on his other ventures. Intrinsic4D and the board of directors thank Mr. Klopp for his years of valuable service as a director. Mr. Klopp will remain as an advisor to Intrinsic4D.

To replace Mr. Klopp, Dr. Adam Folbe has been appointed to the board of directors. Dr Folbe is the Director of Rhinology and Endoscopic Skull Base Surgery at Wayne State University School of Medicine and an Assistant Professor in the department of Otolaryngology-Head and Neck Surgery. Dr. Folbe also serves as chairman of the cancer committee at Karmanos Cancer Institute. Dr. Folbe did a fellowship in Rhinology and endoscopic skull base surgery at the University of Miami (Florida). He completed his undergraduate work at the University of Michigan.

The board of directors has also approved the grant of 200,000 stock options to David Mitchell, a director of Intrinsic4D, at an exercise price of $0.20 per common share and expiring on June 15, 2026. The options and underlying common shares will be subject to a four month hold period from the date of issuance of the option.

About Intrinsic4D Inc.

Intrinsic4D through its Authentic brand, is the developer of the patented and FDA-cleared transformative software-as-a-service medical platform servicing the medical-legal industry and through its patented and disruptive Stenosis Severity Mapping (SSM) Cardio solution aims to reduce the $13 billion of unnecessary cardiac catheterizations performed annually, attributed to false positive reads of diagnostic tests for evaluating coronary artery disease.

Intrinsic4D website - www.intrinsic4d.com

Disclaimer for Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable securities laws. Forward-looking information may relate to Intrinsic4D's future outlook and anticipated events or results. Particularly, statements regarding future results, performance, achievements and prospects or opportunities for Intrinsic4D are forward looking statements. Although the forward-looking statements contained in this press release are based upon assumptions that management of Intrinsic4D believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are beyond Intrinsic4D's control, which may cause actual results to differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements made in this press release relate only to events or information as of the date hereof. Except as required by applicable law, Intrinsic4D undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information